Regulatory
Bridge Therapeutics Inc. announced that it has received feedback from the Food and Drug Administration from a Pre-Investigational New Drug meeting for the development of BT-219, a therapy to treat Opioid Dependence.
Reston Hospital Center Nationally Recognized With An ‘A’ Hospital Safety Grade by The Leapfrog Group
Reston Hospital Center was awarded an ‘A’ Leapfrog Hospital Safety Grade for fall 2019, a national distinction recognizing Reston’s achievements in protecting patients from harm and providing safer health care..
Polarean Imaging plc, the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, announces that the enrolment for its Phase III non-inferiority clinical trials (the “Clinical Trials”) is now complete for both the lung transplant pathway and the lung resection pathway.
The division previously had three clinical divisions and one nonclinical division. Under the restructuring, it will six divisions, three for oncology.
Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.
Shanghai Green Valley Pharmaceuticals announced that China’s National Medical Products Administration has approved Oligomannate as new drug for the treatment of mild to moderate Alzheimer’s disease.
Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA
AVEO said it received preliminary feedback from the FDA and the regulatory agency recommended not filing the NDA at this time based on its assessment of the totality of evidence in the Phase III trial.
Late Friday, President Donald Trump put forth Hahn’s name to take over the top spot of the nation’s regulatory agency.
An international team of researchers have put forward a position statement, published in Science, whichlays out a new healthcare framework to help aging populations stay healthier for longer.
PRESS RELEASES